(Q33575506)

28 July 2017

1 reference

title

Cost considerations in the pharmacological prevention and treatment of stroke (English)

1 reference

28 July 2017

Alexandrov AV

1

1 reference

28 July 2017

Smurawska LT

series ordinal

2

1 reference

28 July 2017

Bartle W

series ordinal

3

1 reference

28 July 2017

Oh P

series ordinal

4

1 reference

28 July 2017

publication date

1 May 1997

1 reference

28 July 2017

1 reference

28 July 2017

volume

11

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

408-418

1 reference

Diabetes as a risk factor for stroke. A population perspective.

28 July 2017

cites work

1 reference

12 December 2020

Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications

1 reference

12 December 2020

The economics of dying. The illusion of cost savings at the end of life

1 reference

12 December 2020

Antithrombotic therapy for ischemic cerebrovascular disease

1 reference

12 December 2020

The strange story of aspirin and the prevention of stroke

1 reference

12 December 2020

Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?

1 reference

12 December 2020

Considerations regarding the cost and effectiveness of public and patient education programmes

1 reference

12 December 2020

1 reference

12 December 2020

Tissue plasminogen activator for acute ischemic stroke

1 reference

12 December 2020

The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. A community-based study

1 reference

12 December 2020

Relative benefits of ticlopidine and aspirin

1 reference

12 December 2020

Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group

1 reference

12 December 2020

Incidence rates of stroke in the eighties: the end of the decline in stroke?

1 reference

12 December 2020

Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension

1 reference

12 December 2020

The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials

1 reference

12 December 2020

Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.

1 reference

12 December 2020

Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis

1 reference

12 December 2020

"Brain attack": the rationale for treating stroke as a medical emergency

1 reference

12 December 2020

Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension

1 reference

12 December 2020

Ticlopidine, trials, and torture

1 reference

12 December 2020

Geographic distribution of hospitalization rates, case fatality, and mortality from stroke in the United States

1 reference

12 December 2020

The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal

1 reference

12 December 2020

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

12 December 2020

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

1 reference

12 December 2020

Stroke subtypes among Chinese living in Hong Kong: the Shatin Stroke Registry

1 reference

12 December 2020

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

1 reference

12 December 2020

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

1 reference

12 December 2020

Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study

1 reference

12 December 2020

Antithrombotic therapy in cerebrovascular disease

1 reference

12 December 2020

On the costs of treating mild hypertension

1 reference

12 December 2020

Cost of acute stroke care in Toronto, Canada

1 reference

12 December 2020

Blood pressure, stroke, and coronary heart disease

1 reference

12 December 2020

Stroke prevention. An opportunity for efficient utilization of health care resources during the coming decade

1 reference

12 December 2020

Stroke Prevention in Atrial Fibrillation Study. Final results

1 reference

12 December 2020

Immediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group

1 reference

12 December 2020

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

12 December 2020

Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window

1 reference

12 December 2020

Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke

1 reference

12 December 2020

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group

1 reference

12 December 2020

Intravenous heparin for the prevention of stroke progression in acute partial stable stroke

1 reference

12 December 2020

Do stroke units save lives?

1 reference

12 December 2020

Thrombolytic therapy with streptokinase in acute ischemic stroke.

1 reference

12 December 2020

Secular trends in stroke incidence and mortality. The Framingham Study

1 reference

12 December 2020

Drugs and surgery in the prevention of ischemic stroke

1 reference

12 December 2020

Antithrombotic therapies for stroke prevention.

1 reference

12 December 2020

Emergency brain resuscitation. A Working Group on Emergency Brain Resuscitation

1 reference

12 December 2020

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

12 December 2020

Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective

1 reference

12 December 2020

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials

1 reference

12 December 2020

10.2165/00019053-199711050-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1049464609

0 references

1 reference